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Abstract Gas chromatography with mass spectrometric
detection combined with head-space needle trap extraction
as the pre-concentration technique was applied to identify
and quantify volatile organic compounds released or me-
tabolised by human umbilical vein endothelial cells.
Amongst the consumed species there were eight aldehydes
(2-methyl 2-propenal, 2-methyl propanal, 2-methyl butanal,
3-methyl butanal, n-hexanal, benzaldehyde, n-octanal and n-
nonanal) and n-butyl acetate. Further eight compounds
(ethyl acetate, ethyl propanoate, ethyl butyrate, 3-heptanone,
2-octanone, 2-nonanone, 2-methyl-5-(methylthio)-furan and
toluene) were found to be emitted by the cells under study.
Possible metabolic pathways leading to the uptake and
release of these compounds by HUVEC are proposed and
discussed. The uptake of aldehydes by endothelial cells
questions the reliability of species from this chemical class as
breath or blood markers of disease processes in human
organism. The analysis of volatiles released or emitted by
cell lines is shown to have a potential for the identification
and assessment of enzymes activities and expression.
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Introduction
There is considerable evidence that volatile organic com-
pounds (VOCs) released by human organism mirror normal
physiological processes as well as pathological disorders
and have, thereby, a great potential for medical diagnosis
and therapy [1–4]. Breath analysis holds in this context a
distinguished status as it is non-invasive and some breath
constituents have already been linked to various disease
processes [5–10]. The main obstacle limiting the clinical
application of breath tests is the insufficient understanding
of the origin and metabolic fate of breath markers. In vitro
studies involving pathogenic microorganisms (e.g. bacte-
ria, fungi) or human cells (both normal and cancerogenous)
are, within this framework, an invaluable tool capable of
revealing the biochemical pathways of breath biomarkers
production or metabolism. For instance, over the last few
years, a substantial progress was made to pinpoint volatiles
emitted or consumed by cancer cells [11–16], bacteria [17,
18], or fungi [19].
In the current study, human umbilical vein endothelial
cells (HUVEC) were investigated. These cells are isolated
from the vein of the umbilical cord and are commonly used
for physiological and pharmacological investigations [20–
22]. In breath gas analysis, endothelial cells play a crucial
role as they form the interior surface of the vascular sys-
tem—a trunk line transporting volatile markers from
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distant parts of the body to lungs. Consequently, the uptake
and release of VOCs by these cells can considerably
modify the profile of blood and breath VOCs and, thereby,
distort the information they provide. Hence, the main goal
of this work was to identify and quantify volatile organic
compounds being emitted or metabolised by human
umbilical vein endothelial cells. Their determination relied
on gas chromatography with mass spectrometric detection
(GC–MS) and head-space needle trap extraction (HS-NTE)
as the pre-concentration method.
Materials and Methods
Chemicals and Standards
Calibration mixtures were prepared from high-purity liquid
substances. The majority of them were purchased from
Sigma-Aldrich (Austria): 2-methyl 2-propenal (95 %),
2-methyl propanal (99.5 %), 3-methyl butanal (97 %),
n-hexanal (98 %), n-octanal (99 %), ethyl butyrate (99 %),
toluene (99.8 %) and ethyl acetate (99.9 %). Moreover,
n-butyl acetate (99.7 %), benzaldehyde (99 %), n-nonanal
(95 %), 2-octanone (99.5 %) and 2-methyl butanal (99 %)
were obtained from Fluka (Switzerland), whereas ethyl
propanoate (97 %) was provided by SAFC (USA). 3-hep-
tanone (98 %) was purchased from Alfa Aesar (USA),
2-methyl-5-(methylthio) furan (99 %) from Chemos (Ger-
many) and 2-nonanone (98 %) was purchased from Merck
Schuchardt (Germany).
Gaseous humid calibration mixtures were prepared
using a GasLab calibration mixtures generator (Breitfuss
Messtechnik, Germany). The GasLab consists of an inte-
grated zero air generator, a 2-stage dynamic injection
module, for evaporating a liquid and diluting it with zero
air, and a humidification module enabling the preparation
of gas mixtures at pre-defined humidity levels. When using
pure liquid substances, GasLab produces a flow of up to
10 L/min of complex trace gas mixtures in dry or humid-
ified zero air containing 10 ppb–100 ppm of each solute.
Since in this study the observed levels of compounds of
interest were much lower, pure substances were addition-
ally diluted (1:1,000–1:2,000) with distilled water or
methanol prior to the evaporation. Effectively, humid gas
mixtures (100 % RH at 37 C) with volume fractions
ranging from approximately 0.04 to 150 ppb were used for
the purpose of calibration and validation.
Cell Cultivation
For the experiments human umbilical vein endothelial cells
(HUVEC) passage 5 (P5) from pooled donors were used
(PromoCell, C-12203). After building up a confluent
monolayer (cell density 80–90 %) in a 75 cm2 cell culture
bottle HUVEC were split 1:3 to cultivation glass bottles
coated with 0.2 % gelatin solution (Sigma, G1393). The
cultivation/measurement bottles had diameters of
21 cm 9 5.5 cm 9 11.5 cm (1,000 mL nominal volume,
bottom area of approximately 240 cm2) and are shown in
Fig. 1. The bottles were closed with a special Teflon plug
equipped with a rubber septum enabling the insertion of the
needle trap devices into the head-space of the culture and the
Teflon tube being the inlet of the zero air. The inner end of the
Teflon tube protruded 15–17 cm from the plug into the head-
space volume, whereas the outer end was equipped with a
sterile filter. The cell culture medium (EBM-2, CC-3156,
supplemented with EGM-2 single quotes, CC-4147; both
Clonetics) was changed every other day. After building up a
confluent monolayer in the glass bottles, cells were washed
three times with PBS (PAA, H15-002) and cultured in 30 mL
medium. A glass bottle coated with gelatin solution (no cells)
and filled with medium was used as background control.
HUVEC were incubated for 24–30 h in a humidified atmo-
sphere (37 C and 5 % CO2) and consequently processed for
the GC–MS analyses of the head-space composition. For the
24 to 30 h of cultivation, the bottles were tightly closed to
boost the accumulation of species released by the cells and to
block the gas exchange with the ambient air. Cell viability
counts (trypan blue exclusion method) were performed
immediately after the measurements. In total, 7 experiments
(each involving 1 cell culture and 1 control) were performed.
Head-Space Sampling Procedure and Chromatographic
Analysis
Head-space volatile organic compounds were pre-concen-
trated using three-bed side-hole 23-gauge stainless steel
needle trap devices (NTD) (PAS Technology, Germany)
[23, 24]. All needles were Silcosteel-treated and their
sorbent beds consisted of 1 cm of Tenax TA (80/100
mesh), 1 cm of Carbopack X (60/80 mesh) and 1 cm of
Carboxen 1,000 (60/80 mesh). Prior to the first use, all
NTDs were pre-conditioned at 290 C by flushing them
with high-purity nitrogen (6.0–99.9999 %) for 4 h. Their
re-conditioning was performed before each sampling,
however, with shorter flushing times of 10 min. Since
NTDs exhibited relatively huge disparities with respect to
the extraction efficiency (deviations of up to 70 %, even
when originating from the same production lot), the NTDs
used during experiments were pre-selected according to the
condition that their inter-needle variability should be below
10 %.
The sampling was performed dynamically by inserting
the NTD through a rubber septum into the head-space of
the bottle and drawing 200 mL of head-space gas at a
steady flow rate of 10 mL/min at 37 C. These conditions
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were achieved with the help of a membrane pump (Vac-
uubrand, Germany) and a mass flow controller (RED-Y,
Burde Co. GmbH, Austria). Consequently, no transfer line
was present between the sampled head-space and a needle
trap. To maintain the constant pressure in the bottle during
sampling, high-purity zero air was continuously introduced
into it via the Teflon tube (see Fig. 1) at a flow equal to the
sampling flow. Immediately after an extraction, the NTD
was manually introduced into the inlet of the gas chro-
matograph where the compounds of interest were thermally
desorbed at 290 C in a splitless mode (1 min).
Chromatographic analyses were performed using an
Agilent 7890A/5975C GC–MS system (Agilent, USA).
During desorption, the split/splitless inlet operated in the
splitless mode (1 min), followed by a split mode at ratio
1:20. The analytes were separated using a PoraBond Q
column (25 m x 0.32 mm, film thickness 5 lm, styrene–
divinylbenzene copolymer phase, Varian, USA) working
under a constant flow of helium (1.5 mL/min). The column
temperature programme was as follows: 40 C for 5 min,
increase to 260 C at a rate of 7 C/min, followed by a
constant temperature phase at 260 C for 6 min. The mass
spectrometer worked in a SCAN mode with an m/z range
set from 20 to 200. The quadrupole, ion source and transfer
line temperatures were kept at 150, 230 and 280 C,
respectively.
The identification of compounds was performed in two
steps. First, the peak spectrum was checked against the
NIST mass spectral library (NIST/EPA/NIH mass spectral
library version 2.0f). Next, the NIST tentative identifica-
tions were validated by collating the respective retention
times with the list of retention times obtained on the basis
of analyses of standard mixtures. Peak integration was
based on extracted ion chromatograms. The retention times
Fig. 1 Cultivation/
measurement bottle
Table 1 Retention times Rt (min), quantifier ions, LODs (ppb), RSDs (%), coefficients of variation (R
2) and linear ranges (ppb) of compounds
under study
VOC CAS Rt (min) Quantifier ion LOD (ppb) RSD (%) R
2 Linear range (ppb)
2-Propenal, 2-methyl- 78-85-3 18.99 70 0.03 8 0.993 0.1–12
Propanal, 2-methyl- 78-84-2 19.27 72 0.3 9 0.977 0.9–150
Ethyl acetate 141-78-6 21.00 43 0.12 5.5 0.987 0.36–20
Butanal, 3-methyl- 590-86-3 23.36 44 0.14 9 0.978 0.4–170
Butanal, 2-methyl- 96-17-3 23.42 Not quantified, RT confirmed
Ethyl propanoate 105-37-3 24.64 57 0.04 9 0.998 0.12–1.5
Toluene 108-88-3 26.21 91 0.1 6 0.999 0.3–20
n-Hexanal 66-25-1 27.73 56 0.2 9 0.994 0.6–15
Ethyl butyrate 105-54-4 27.93 71 0.02 9 0.996 0.06–1
n-Butyl acetate 123-86-4 28.18 56 0.04 10 0.997 0.12–8
3-Heptanone 106-35-4 30.51 85 0.03 2.5 0.997 0.09–7
Benzaldehyde 100-52-7 30.87 106 0.05 12 0.998 0.15–12
Furan, 2-methyl-5-(methylthio)- 13678-59-6 31.00 128 0.03 7 0.988 0.09–4
2-Octanone 111-13-7 33.56 58 0.05 9 0.991 0.15–5.5
n-Octanal 124-13-0 33.76 84 0.1 10 0.993 0.3–13
2-Nonanone 821-55-6 36.19 58 0.07 11 0.974 0.21–5.7
n-Nonanal 124-19-6 36.41 57 0.4 12 0.930 1.2–12
Compounds are ordered with respect to increasing retention time
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of the investigated compounds for the applied chromato-
graphic parameters as well as the quantifier ions used for
the integration are presented in Table 1.
Results and Discussion
Validation Parameters
Limits of detection (LODs) were calculated using the mean
value of the blank responses and their standard deviations
obtained on the basis of 10 blank measurements [25]. The
LOD values ranged from 0.02 ppb for ethyl butyrate to
0.3 ppb for 2-methyl propanal, see Table 1. The relative
standard deviations (RSDs) were calculated on the basis of
five consecutive analyses of humid standard mixtures. The
calculated RSDs varied from 2.5 to 12 % and were
recognised as adequate for the aim of this study. The sys-
tem response was found to be linear within the investigated
concentration ranges with the coefficients of variation
ranging from 0.930 to 0.999, as shown in Table 1.
HUVEC Cultures
The total number of HUVEC and their viabilities after 24–30 h
incubation in the closed measurement bottles are shown in
Table 2. The total number of cells fell within the range of 3.3
mio and 45.5 mio (mean 15.8 mio), whereas the viability varied
from 81.4 to 99.8 % (mean 92.7 %). Consequently, the applied
experimental protocol did not affect relevantly the cells’ via-
bility, and it can be assumed that the release and uptake of the
head-space VOCs mirror their metabolism.
Uptake of VOCs by HUVEC
A total of nine species were found to be consumed by the
HUVEC (Wilcoxon signed-rank test, p \ .05). Their inci-
dences and concentration ranges in the head-space of cell
cultures and controls are given in Table 3. The predomi-
nant chemical class in this group were aldehydes with eight
compounds (2-methyl 2-propenal, 2-methyl propanal,
2-methyl butanal, 3-methyl butanal, n-hexanal, benzalde-
hyde, n-octanal and n-nonanal). Apart from aldehydes
there was one ester, n-butyl acetate. In the case of 2-methyl
butanal, proper integration and quantification was not
possible due to the poor separation from 3-methyl butanal
and the absence of unique ion that could be used for these
purposes. Aliphatic and saturated aldehydes seemed to be
more preferred substrates for HUVEC than unsaturated or
aromatic ones. For instance, the levels of n-hexanal and
3-methyl butanal were reduced by approximately 90 %
after the 1-day-long incubation, whereas the concentrations
of 2-methyl 2-propenal and benzaldehyde dropped only by
40 and 60 %, respectively.
A potential pathway leading to the uptake of aldehydes by
HUVEC involves aldehyde dehydrogenases (ALDHs).
ALDHs irreversibly oxidise a wide spectrum of endogenous
and exogenous aldehydes to their corresponding carboxylic
acids [26, 27]. Although ALDHs in endothelial cells are rather
poorly expressed, their activity has been evidenced in the
literature [28, 29]. Moreover, the observed differences in the
uptake of different types of aldehydes are consistent with the
reported specificity of human ALDHs towards species from
this chemical class [26]. Alternatively, aldehydes can be
reduced to alcohols by alcohol dehydrogenases (ADHs).
ADHs were found to be abundant in human blood vessels;
however, their primary function there seems to be the first-
pass extrahepatic ethanol metabolism [30]. Thus, the oxida-
tion rather than reduction appears to be the main reason of the
aldehydes’ uptake noted within this study [30].
The decrease of n-butyl acetate can mirror the activity of
carboxylesterases (CESs), enzymes ubiquitous in human tis-
sues [31]. This ester could be hydrolysed by CESs into acetic
acid and 1-butanol being subsequently converted into n-but-
anal by ADHs, and next butanoic acid by ALDHs.
The uptake of aldehydes has already been noted in
human cells cultures. Filipiak et al. [14, 15] and Sponring
et al. [12] reported the consumption of species from this
chemical family by lung cancer and normal cells. In our
recent paper [16] we evidenced similar phenomenon in
cultures of human hepatocellular carcinoma cells (HepG2).
ALDHs are particularly expressed in both lung and liver
cells [27], moreover, their activity is additionally increased
in their cancer counterparts [32, 33]. Both lung and liver
cells were also shown to metabolise n-butyl acetate during
in vitro studies [12, 14–16].
Emission of VOCs by HUVEC
Eight compounds increased their levels at the presence of
HUVEC (see Table 3). Amongst them there were three
Table 2 Total number of cells, number of living cells and viability at
the end of the cultivation period






1 13.6 13.2 97.4
2 45.5 42.8 93.9
3 3.3 2.7 83.7
4 5.3 4.3 81.4
5 12.8 12.1 94.8
6 14 13.7 97.7
7 15.9 15.9 99.8
Mean 15.8 14.9 92.7
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esters (ethyl acetate, ethyl propanoate and ethyl butyrate),
three ketones (3-heptanone, 2-octanone and 2-nonanone),
one volatile sulphur compound (2-methyl-5-(methylthio)
furan) and one aromatic hydrocarbon (toluene). The high-
est concentrations were observed for ethyl acetate (mean of
10.1 ppb in cell cultures vs. 1.8 ppb in media) and toluene
(7.8 vs. 3.6, respectively). However, the toluene levels
increased only by a factor of two, whereas the ethyl acetate
ones almost six-fold.
Ketones production by the HUVEC can be attributed to
the aforementioned high expression of alcohol dehydro-
genases (ADHs) in human vascular endothelium [30].
Although primary alcohols seem to be the most preferred
substrates for ADHs, they can also oxidise longer-chain
cyclic and secondary alcohols [27, 34–36]. The latter were
shown to be rather poor substrates for ADHs [36], never-
theless their conversion into ketones has been documented in
the literature [34, 36]. Consequently, 2-octanone could be the
product of the 2-octanol oxidation and 2-nonanone possibly
stemmed from 2-nonanol. The origin of these secondary
alcohols remains unclear. Probably they were present in
small amounts in the applied medium. An alternative path-
way leading to the formation of ketones in humans employs
b-oxidation of branched-chain fatty acids. For example,
valproic acid was demonstrated to be metabolised into
3-heptanone [37] and 2-ethylhexanoic acid was reported to
be oxidised to 2-heptanone and 4-heptanone [38]. The
respective branched-chain fatty acids can in turn be the
metabolites of the appropriate branched-chain primary
alcohols or/and aldehydes (e.g. 2-propyl pentanol or 2-pro-
pyl pentanal in case of 3-heptanone). However, it is not clear
if these substrates were present in the applied medium.
Interestingly, all esters found to be released by HUVEC
stemmed from ethanol. Indeed, huge amounts of this
alcohol (exceeding the dynamic range of the MS detector)
were detected in the head-space of both cell cultures and
blanks. Consequently, it seems plausible that the esterifi-
cation reaction involving ethanol and the respective fatty
acids could induce the production of the observed esters.
Although such a reaction in the absence of a catalyst is very
slow and the products relatively unstable, small amounts of
esters could form and go into the gas phase. Thus, ethyl
acetate was presumably generated by a reaction of ethanol
with acetic acid—a product of the oxidation of the former
by a tandem of ADHs and ALDHs. The high concentra-
tions of ethyl acetate as compared with the other liberated
esters seem to confirm this hypothesis. Analogously,
propanoic and butanoic acids—substrates necessary for the
production of the remaining esters—could in turn be pro-
duced from 1-butanol and 1-propanol (or n-propanal and
n-butanal). Apart from 1-butanol, all these potential sub-
strates were found in the head-space of the cell cultures.
Consequently, the release of esters seems to be an indirect
reflection of ADH and ALDH activities.
Table 3 Detection (nd) and
quantification (nq) incidences
and ranges (means) of VOCs
under study in the head-space of
medium and cell cultures










2-Propenal, 2-methyl- 78-85-3 7(5) 0.67–3.1(1.5) 7(7) 0.9–4.1(2.4)
Propanal, 2-methyl- 78-84-2 7(7) 1.5–16(5.6) 7(7) 16–125 (56)
Butanal, 3-methyl- 590-86-3 6(6) 1.2–17.2(5.3) 7(7) 1.7–95.5(44)
n-Hexanal 66-25-1 7(6) 0.7–3(1.5) 7(7) 5.8–15.5(9.8)
n-Butyl acetate 123-86-4 7(4) 0.13–0.58(0.38) 7(7) 0.15–0.88(0.52)
Benzaldehyde 100-52-7 7(7) 0.17–1.1(0.48) 7(7) 0.63–2.53(1.2)
n-Octanal 124-13-0 4(0) \LOQ 7(7) 0.32–3.34(0.98)
n-Nonanal 124-19-6 1(0) \LOQ 7(6) 1.8–2.2(2.0)
Release
Ethyl acetate 141-78-6 7(7) 3.7–16.2(10.1) 7(7) 0.5–3.2(1.8)
Ethyl propanoate 105-37-3 7(7) 0.14–0.90(0.49) 6(0) \LOQ
Toluene 108-88-3 7(7) 1.8–18.6(7.8) 7(7) 1.2–5.9(3.6)
Ethyl butyrate 105-54-4 7(6) 0.07–0.22(0.16) 1(0) \LOQ





7(7) 0.11–0.36(0.25) 0(0) \LOD
2-Octanone 111-13-7 7(6) 0.18–0.39(0.28) 7(1) 0.16
2-Nonanone 821-55-6 7(6) 0.25–0.50(0.37) 6(0) \LOQ
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The origin of toluene and 2-methyl-5-(methylthio)-
furan remains unclear; however, the latter was found to be
produced also by human hepatocellular carcinoma cells
[16].
The release of ketones was reported also in case of lung
and liver cells [13, 15, 16], which is consistent with the
ADHs’ expression in different human tissues [27]. In terms
of esters, both cancer liver and lung cells were evidenced to
emit n-propyl acetate [15, 16].
Conclusions
In the present study, gas chromatography with mass
spectrometric detection coupled with head-space needle
trap extraction (HS-NTE) as the pre-concentration tech-
nique was applied for the identification and quantification
of volatiles being released or metabolised by human
umbilical vein endothelial cells (HUVEC). Seventeen
VOCs were found to change their levels in the presence
of HUVEC cells (Wilcoxon signed-rank test, p \ .05).
Amongst the consumed species, there were eight alde-
hydes (2-methyl 2-propenal, 2-methyl propanal, 2-methyl
butanal, 3-methyl butanal, n-hexanal, benzaldehyde, n-
octanal and n-nonanal) and n-butyl acetate. Eight com-
pounds were emitted by the cells under study. This group
embraces three esters (ethyl acetate, ethyl propanoate and
ethyl butyrate), three ketones (3-heptanone, 2-octanone
and 2-nonanone), one volatile sulphur compound (2-
methyl-5-(methylthio) furan) and one aromatic hydrocar-
bon (toluene). The uptake and release of majority of these
analytes can be attributed to the expression of enzymes in
the endothelial cells, such as ADHs and ALDHs. Thus,
the analysis of volatiles released or emitted by cell lines
has a potential for the identification and assessment of
enzymes activities.
The uptake of aldehydes by HUVEC is particularly
interesting as some species from this chemical class (e.g. n-
pentanal, n-hexanal, n-heptanal and n-octanal) have been
proposed as blood and breath biomarkers of various forms
of cancer [28, 39–42] or oxidative stress [43, 44]. The
human vascular endothelium exhibits enormous surface of
500–700 m2 [30]. Consequently, it is likely that blood
vessels reduce significantly the blood levels of aldehydes in
general and disease-related aldehydes in particular. This
observation questions aldehydes as reliable markers pro-
viding the information on disease processes, or metabolic
disorders occurring in distant parts of the body. Moreover,
in the context of breath gas analysis, the vascular system
cannot be considered as an inert trunk line transporting
volatile markers to lungs. Thus, the selection of new breath
markers should embrace the studies on their stability in
blood and vascular system.
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